Equillium Analyst Price Targets

Wall Street analyst price targets and consensus rating for Equillium (EQ).

Price Target Range — 8 Quarters

Analyst Consensus — 7 Analysts

1S.Buy

5Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$9Upside to Avg. PT+562.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	Leerink Partners	Will Soghikian	Assumes	Outperform	$6
Sep 4, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$12
Jul 13, 2026	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$20
Jun 2, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$12
May 28, 2026	Leerink Partners	Thomas Smith	Upgrade	Market Perform→Outperform	$1→$6
May 28, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$12
Apr 17, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$12
Apr 16, 2026	B. Riley Securities	William Woods	Initiate	Buy	$6
Apr 14, 2026	Raymond James	Martin Auster	Initiate	Strong Buy	$6
Mar 13, 2026	Roth Capital	Adam Walsh	Initiate	Buy	$12
Mar 28, 2025	Leerink Partners	Thomas Smith	Downgrade	Outperform→Market Perform	$3→$1
Nov 1, 2024	Jones Trading	Catherine Novack	Downgrade	Buy→Hold	—
Aug 19, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$5
Jun 5, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$5
May 17, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$5
Apr 2, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$4→$5
Dec 26, 2023	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$5→$4
Nov 13, 2023	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$6→$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6

Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.

Benzinga Newsdesk

PRO
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Equillium (NASDAQ:EQ) with a Overweight rating and announces Price Target of $20.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.

Benzinga Newsdesk

PRO
Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6

Leerink Partners analyst Thomas Smith upgrades Equillium (NASDAQ:EQ) from Market Perform to Outperform and raises the price target from $1 to $6.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.

Benzinga Newsdesk

Equillium Inc

Equillium Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

PRO
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

PRO
Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

People Also Watch

People Also Watch

Equillium Inc

Equillium Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Assumes Equillium at Outperform, Announces Price Target of $6

PRORoth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

PROPiper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20

PRORoth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

PROLeerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6

PRORoth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

People Also Watch

People Also Watch

PRO
Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

PRO
Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

PRO
Leerink Partners Upgrades Equillium to Outperform, Raises Price Target to $6

PRO
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target